Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

NCT05301881 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT05301881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05301881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 2
Overall status
Recruiting
Start date
April 17, 2023
Completion date
April 1, 2040
Enrollment
56 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer invasive, metastatic cancer, oligoprogressive